Autoinjectors Market - Global Industry Analysis

Description

Table Of Content

Methodology

Free Analysis

Autoinjectors are medical devices designed to administer a dose of a specific drug to patients. Autoinjectors are proposed for self-administration of drug dosage by patients. They are easy to use and can be operated by even an untrained person. The autoinjector is designed in such a way that the needle tip remains protected before the drug is injected. These autoinjectors have a passive protection mechanism to stop accidental injection. The syringe needle is inserted by pressing a button for delivering the drug. Autoinjectors comprise glass syringes that make them prone to infection and fragile.

The increasing adoption of targeted therapy, growing anaphylaxis incidences, growing regulatory approvals, simplifying self-administration, increasing biologics use for drug delivery, rising cancer and diabetes cases, advantageous reimbursement scenario, and the availability of generic autoinjectors are likely to be major factors driving the growth of the global autoinjectors market. Patent expiry of current products and technological improvements related to autoinjectors due to an increased focus on research and development is anticipated to further fuel the autoinjectors market globally in the future. Nonetheless, the growing use of alternative modes of drug delivery, infections and injuries caused due to needle-stick, and multiple regulatory might restrict the growth of the global autoinjectors market in the upcoming years.

The global autoinjectors market is split based on type, technology, therapy, design, and end-user. By type, the autoinjectors market is segmented into reusable autoinjectors and disposable autoinjectors. Disposable autoinjectors are likely to grow rapidly over the forecast time period. The technology segment includes manual autoinjectors and automated autoinjectors. The therapy segment includes multiple sclerosis, rheumatoid arthritis, anaphylaxis, diabetes, and others. The design segment includes customized autoinjectors and standardized autoinjectors. The end-user segment includes hospital and clinics and home care settings. Home care settings are expected to hold the largest share of the global market, owing to the rising use of autoinjectors for self-administration of drugs, technological advancements in the autoinjectors, and increasing prevalence of chronic disorders.

By region, the North American autoinjectors market is likely to lead over the forecast time period. This can be attributed to the growing incidence of anaphylaxis in the U.S., increasing number of FDA approvals, and rising prevalence of chronic and autoimmune disorders, increased biologics use for drug delivery, and growing use of self-administered drugs. Europe is likely to emerge as the second largest market in the future, owing to the growing geriatric population, increasing cancer and diabetes cases, advantageous reimbursement scenario, and growing prescriptions for adrenaline autoinjectors. The Asia Pacific region is anticipated to propagate at a speedy rate over the forecast time period, due to the increasing cases of chronic disorders, such as diabetes, growing awareness regarding self-administration of drugs, increasing cases of rheumatoid arthritis, and the availability of generic versions of autoinjectors. The Latin American autoinjectors market is projected to develop significantly over the forecast time period. The Middle Eastern and African countries are likely to experience perceptible growth over the estimated timeframe.

Some key players of the global autoinjectors market include Eli Lilly, Abbvie, Biogen, Teva, Mylan, Merck, Ypsomed, SHL Group, Becton Dickinson and Company, and Novartis, among others.